Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted. The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov. Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

NLM Logo

N-(2-(4-((3-chloro-4-(3-(trifluoromethyl)phenoxy)phenyl)amino)-5H-pyrrolo(3,2-d)pyrimidin-5-yl)ethyl)-3-hydroxy-3-methylbutanamide MeSH Supplementary Concept Data 2025


MeSH Supplementary
N-(2-(4-((3-chloro-4-(3-(trifluoromethyl)phenoxy)phenyl)amino)-5H-pyrrolo(3,2-d)pyrimidin-5-yl)ethyl)-3-hydroxy-3-methylbutanamide
Unique ID
C570404
RDF Unique Identifier
http://id.nlm.nih.gov/mesh/C570404
Entry Term(s)
TAK 285
TAK-285
TAK285
Registry Numbers
70CCB438L6
Heading Mapped to
*Hydroxybutyrates
*Bridged Bicyclo Compounds, Heterocyclic
Frequency
10
Note
also inhibits HER2; structure in first source
Source
J Med Chem. 2011 Dec 8;54(23):8030-50.
Indexing Information
ErbB Receptors
Date of Entry
2012/03/01
Revision Date
2018/09/24
N-(2-(4-((3-chloro-4-(3-(trifluoromethyl)phenoxy)phenyl)amino)-5H-pyrrolo(3,2-d)pyrimidin-5-yl)ethyl)-3-hydroxy-3-methylbutanamide Preferred
TAK 285 Narrower
page delivered in 0.004s